1. To learn about functional imaging (perfusion, DWI, PET) in head and neck cancer patients.
2. To understand the value of functional imaging for tumour assessment.
3. To discuss nodal assessment in head and neck cancer.
Head and neck cancer is one of the most common cancers worldwide. MRI based diffusion and perfusion techniques enable the non-invasive assessment of tumour biology and physiology and add additional information to standard structural MRI scans. Head and neck squamous cell carcinoma may cause a decreased apparent diffusion coefficient (ADC) on diffusion-weighted magnetic resonance imaging (DW MRI) and an increased standardised uptake value (SUV) on fluorodeoxyglucose (FDG) positron emission tomography (PET/CT). These techniques can improve the initial staging and can help to monitor treatment response. In addition, these techniques can improve patient selection for therapeutic strategies and provide evidence for a change of therapy regime. This presentation summarizes recent literature and provides an overview of the various studies in which diffusion or perfusion-based MRI studies are applied to head and neck cancer and will provide an overview of commonly used acquisition protocols and postprocessing methods, followed by advanced data analysis, imaging findings regarding tumour characterization and differentiation, tumour risk stratification and staging, monitoring and prediction of treatment response. Limitations will be highlighted followed by a conclusion with recommendations for the future.
1. To become familiar with the incidence of the synchronous tumours in the head and neck population.
2. To become familiar with the incidence of the distant metastases in the patients with newly diagnosed head and neck cancer.
3. To understand the consequences in a prognosis.
Second primary tumours Head & neck cancer has one of the highest associations with second primary tumours (SPT). SCC is associated with smoking and high alcohol intake, and so patients are also at risk of SPTs in other sites of the head & neck, lung and oesophagus. Less commonly SPTs arise in the colon, pancreas and bladder. SPTs are usually metachronous with synchronous tumours being diagnosed in only ~ 4% of patients. SPTs are a leading cause of death in patients with early-stage SCC, but SPTs detected early are potentially curable. Distant metastases With advances in locoregional control distant metastases (DM) now are emerging as a major determinant of survival. Therefore, a more active approach is being taken to detect and manage distant site disease, including the use of a new generation of immunotherapy agents. The incidence, risk factors, sites, prognosis, and management of DM vary with histology and will be discussed in three main groups comprising carcinomas of the aerodigestive tract, thyroid and salivary glands. Most DM manifest after initial treatment, the most common sites being lung or bone, followed by the liver. Prognosis tends to be poor with most patients succumbing to disease within a year. However, the prognosis is dependent on many factors which include histology, site and number of DM. Notably, some patients survive, and there is a subgroup of patients with oligometastases who have a potentially curable disease.
1. To review the advanced imaging for detection of distant metastases of head and neck cancer.
2. To understand the advantages and disadvantages of functional imaging modalities for M staging.
3. To discuss when to image for distant metastases.